Literature DB >> 12907245

The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide.

Cheryl Brantley-Finley1, Christopher S Lyle, Lihua Du, Mary E Goodwin, Toria Hall, Dominika Szwedo, G P Kaushal, Timothy C Chambers.   

Abstract

Assessment of specific apoptosis and survival pathways implicated in anticancer drug action is important for understanding drug mechanisms and modes of resistance in order to improve the benefits of chemotherapy. In order to better examine the role of mitogen-activated protein kinases, including JNK and ERK, as well as the tumor suppressor p53, in the response of tumor cells to chemotherapy, we compared the effects on these pathways of three structurally and functionally distinct antitumor agents. Drug concentrations equal to 50 times the concentration required to reduce cell proliferation by 50% were used. Vinblastine, doxorubicin, or etoposide (VP-16) induced apoptotic cell death in KB-3 carcinoma cells, with similar kinetic profiles of PARP cleavage, caspase 3 activation, and mitochondrial cytochrome c release. All three drugs strongly activated JNK, but only vinblastine induced c-Jun phosphorylation and AP-1 activation. Inhibition of JNK by SP600125 protected cells from drug-induced cytotoxicity. Vinblastine caused inactivation of ERK whereas ERK was unaffected in cells exposed to doxorubicin or VP-16. Inhibition of ERK signaling by the MEK inhibitor, U0126, potentiated the cytotoxic effects of vinblastine and doxorubicin, but not that of VP-16. Vinblastine induced p53 downregulation, and chemical inhibition of p53 potentiated vinblastine-induced cell death, suggesting a protective effect of p53. In contrast, doxorubicin and VP-16 induced p53, and inhibition of p53 decreased drug-induced cell death, suggesting a pro-apoptotic role for p53. These results highlight the differential roles played by several key signal transduction pathways in the mechanisms of action of key antitumor agents, and suggest ways to specifically potentiate their effects in a context-dependent manner. In addition, the novel finding that JNK activation can occur without c-Jun phosphorylation or AP-1 activation has important implications for our understanding of JNK function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907245     DOI: 10.1016/s0006-2952(03)00255-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  35 in total

1.  Tethering function of the caspase cleavage fragment of Golgi protein p115 promotes apoptosis via a p53-dependent pathway.

Authors:  Poh Choo How; Dennis Shields
Journal:  J Biol Chem       Date:  2010-12-08       Impact factor: 5.157

2.  Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas.

Authors:  Pritha Paul; Lauren A Gillory; JungHee Kang; Jingbo Qiao; Dai H Chung
Journal:  Surgery       Date:  2010-10-29       Impact factor: 3.982

3.  B7-H4 downregulation induces mitochondrial dysfunction and enhances doxorubicin sensitivity via the cAMP/CREB/PGC1-α signaling pathway in HeLa cells.

Authors:  Hyoung Kyu Kim; In-Sung Song; Sun Young Lee; Seung Hun Jeong; Sung Ryul Lee; Hye Jin Heo; Vu Thi Thu; Nari Kim; Kyung Soo Ko; Byoung Doo Rhee; Dae Hun Jeong; Young Nam Kim; Jin Han
Journal:  Pflugers Arch       Date:  2014-12       Impact factor: 3.657

Review 4.  Adding more content to screening: reactivation of FOXO as a therapeutic strategy.

Authors:  Fabian Zanella; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-10       Impact factor: 3.405

5.  Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells.

Authors:  Fuminori Teraishi; Lidong Zhang; Wei Guo; Fengqin Dong; John J Davis; Anning Lin; Bingliang Fang
Journal:  FEBS Lett       Date:  2005-11-14       Impact factor: 4.124

6.  Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts.

Authors:  Maria Isabel Cerezo-Guisado; Natalia García-Román; Luis Jesús García-Marín; Alberto Alvarez-Barrientos; Maria Julia Bragado; Maria Jesús Lorenzo
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

Review 7.  Microtubule destabilising agents: far more than just antimitotic anticancer drugs.

Authors:  Darcy Bates; Alan Eastman
Journal:  Br J Clin Pharmacol       Date:  2016-10-18       Impact factor: 4.335

8.  Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.

Authors:  Jan N Kreutzer; Maria Ruzzene; Barbara Guerra
Journal:  BMC Cancer       Date:  2010-08-19       Impact factor: 4.430

9.  A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.

Authors:  Jessica E Pritchard; Patrick M Dillon; Mark R Conaway; Corinne M Silva; Sarah J Parsons
Journal:  Oncology       Date:  2012-09-05       Impact factor: 2.935

10.  Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model.

Authors:  Tao Chen; Shen-Jun Yuan; Jing Wang; Wei Hu
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.